drugset / Trial / NCT02077868

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

NCT02077868

Phase 3 Unknown 540 enrolled Mologen AG
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.

Timeline

Start
2014-09
Primary completion
2019-02
Completion
2020-05

Drugs

EvaluationDrugModalityDoseRoute
Subject lefitolimod Oligonucleotide (other)

Indications